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Fig. 1. Specificity was examined by mixing together the high, medium and low
quality control samples (mQC). This mixture was serially diluted at the following
dilutions: 1:2, 1:4, 1:8, and 1:10. The results of this serial dilution were then
compared to the standard curve that was derived using the standards provided
by the manufacturer by comparing the absorbance to the concentration. The
samples demonstrated parallelism to the master standard curve.
Fig. 2. Linearity of dilution was analyzed by serially diluting QC samples (high,
medium, and low) at the following dilutions: 1:2, 1:4, 1:8, and 1:10. The concen-
tration of each dilution was then determined from the standard curve and the
observed concentration was plotted against the reciprocal of the dilution (1/dilu-
tion).
2). There was no loss in the stability of the CTX II epitope
out to 4 freeze/thaw cycles. Differences in biological activity
were identified when examining SF samples from normal rested
horses (291 ± 58.5 pg/ml), horses treadmill exercised for 4
months (330.8 ± 124 pg/ml), and those with naturally-occurring
OC injuries (690.0 ± 69.3 pg/ml).
Conclusions: The Serum Pre-Clinical Cartilaps® ELISA is a
reproducible and valid assay for use with equine synovial fluid.
Acknowledgements: Study supported by Pfizer, Inc, Animal
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Purpose: To date, autologous chondrocyte transplantation (ACT)
is mainly used for the treatment of post-traumatic cartilage de-
generation or of osteochondrosis dissecans (OD). First studies
suggest that ACT might also be used for the treatment of os-
teoarthritis (OA). However, it is still unclear if the environment
in the osteoarthritic joint might hamper cartilage regeneration.
Therefore, we compared matrix metalloproteases (MMP) and cy-
tokine levels in synovial fluid from patients currently treated with
ACT with those of patients with generalized, primary OA or with
unilateral OA combined with axis-malalignment.
Methods: Knee synovial fluid (SF) was collected from OD-
patients (n=6, 33 ± 10 years), post-traumatic cartilage
degeneration-patients (n=9, 39 ± 12 years), unilateral OA-
patients (n=12, 53 ± 17 years), and primary OA-patients (n=19,
71 ± 9 years). Samples were collected before the cartilage
harvest for ACT, during diagnostical arthroscopy or before total
knee replacement, immediately frozen, and stored at -70°C until
measurement.
The concentration of cytokines and MMPs were determined
using a multiplex assay based on antibody-coated microspheres
(xMAP® Technology, Luminex, USA). IL-1β, IL-6, IL-8, IL-10,
IL-12 and TNFα were measured with the Beadlyte® Human
Multi-cytokine Detection System 2 (Upstate USA, Lake Placid,
NY); MMP-1, -2, -3, -7, -8, -9, -10, and -13 were measured
using a multiplexed bead-based assay system developed at our
institute.
Results: In SF of all four groups, high concentrations of MMP-
1, -3 and -9 (av. 119.7, 471.9, 1311.8 ng/ml respectively), and
medium levels of MMP-7 (av. 20.6 ng/ml) were present; MMP-10
(av. 0.4 ng/ml) was only present at very low levels, while MMP-
2, -8, and -13 could not be detected. No differences could be
detected between the different groups, except that MMP-levels
in SF from OD-patient appeared to be generally lower than
OA and traumatic cartilage degeneration. However, this only
reached significance for MMP-3 compared with post-traumatic
cartilage degeneration. IL-6 was the cytokine found in highest
concentration in the SF of most of the patients (av. 284.8 pg/ml).
In all groups IL-8 was present in medium levels (av. 39.6 pg/ml),
while IL-1β, IL-10, IL-12 and TNFα were present at baseline (av.
3.6-16.8 pg/ml). Again, no differences between the four groups
were found.
Conclusions: We conclude that although both inflammatory
cytokines and MMPs were present in the SF of all patients,
the levels of those did not differ between the OA, the post-
trauma and OD groups. Since patients of the last two groups are
routinely treated with the ACT with good results, the presence
of these cytokines and MMPs does not hamper the success of
this method. It might therefore be expected that the metabolic
environment in OA patients also would not prevent the usage of
ACT in these patients.
Acknowledgements: This work is supported by the BMBF (grant
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Purpose: Urine levels of C telopeptides of type I (CTX I) and II
(CTX II) collagens have been shown to be useful for the moni-
toring of patients with bone and articular diseases respectively.
The aim of the study was to assess differences of CTX I and
CTX II urine concentrations according to the musculoskeletal
diseases, and to investigate whether the levels of the biomarkers
can help for diagnosis.
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Methods: Urine samples were obtained in 354 consecutive
patients, referred to the department of rheumatology for one of
the following diseases [Osteoarthritis (OA), rheumatoid arthritis
(RA), ankylosing spondylitis (AS), undetermined inflammatory
arthritis (UIA), osteoporosis (OP)] and in 66 controls (CTRL).
CTX I and II were assayed using a competitive ELISA method.
CTX I and II correlations were studied by linear regression.
Differences in CTX levels between groups were studied with
analysis of variance, taking into account age, sex and BMI.
Results: Cross sectional study. 144 males and 276 females;
mean (SD) age 59(17); mean CTX I 228.9 (204) ng/mL; mean
CTX II 375.7(408.6) ng/mL.
CTX I was significantly higher in females than in males (p=0.006).
There was a correlation between CTX I and CTX II concentra-
tions (R=0.34, p<0.001). CTX I but not CTX II was correlated
with age (p=0.001 and p=0.46 respectively).
CTX I was significantly higher in OP than in CTRL (p=0.02).
However there was no significant difference of CTX I levels
between OP and OA, RA, SA and UIA. CTX I levels were not
statistically different between CTRL and the various articular
diseases.
CTX II concentrations were higher in all the articular diseases
than in CTRL (OA/CTRL p=0.05; RA/CTRL p=0.02; AS/CTRL
p=0.004, UIA/CTRL p=0.02) but no difference was found between
OP and CTRL (p=0.3).
Lastly CTX II levels were not significantly different between OA,
RA, SA and UIA. (all p> 0.2).
Conclusions: Both CTX I and II were increased in muscoskeletal
diseases. Compared to CTRL, CTX I levels were signifcantly
increased only in patients with OP.
By contrast CTX II were significantly increased in OA, inflamma-
tory rheumatisms but also OP. Surprisingly CTX II was as high
in OP as in inflammatory diseases and in OA. The influence of
the treatments on CTX levels remains to be investigated.
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Purpose: Structure analysis of serum chondroitin sulfate (CS)
is very important as information could be received in respect to
structural alterations of serum CS in several pathological condi-
tions along with its pharmacological profile. Due to the low blood
concentration of CS and a general lack of adequate analytical
methodology that ensures high recovery of CS and sensitive
determination, the factors influencing its structure and concen-
tration have not yet been fully identified. Furthermore, the safety
and purity of CS preparations from various sources should be
addressed since they are widely used as nutritional supplements
and drugs.The aim of this study was therefore to develop: 1) a
high sensitive assay that can be used for identification and deter-
mination of hyaluronan (HA) contamination in CS commercially
available preparations and 2) a serum pretreatment procedure
and an accurate analytical methodology for the determination of
total CS and its disaccharide composition in serum.
Methods: A reversed polarity capillary electrophoresis (CE) ap-
proach has been developed for purity analysis of CS preparations
from various tissues as well as for monitoring the variously sul-
phated CS disaccharides in blood circulation. Charge density
distribution of CS preparations and purity testing for identification
of HA was performed by direct CE analysis of aqueous CS solu-
tions. For analysis of serum samples, they were treated with pro-
tease and CS chains were completely recovered by precipitation.
CS were selective degraded to variously sulphated disaccharides
following enzymic digestion of with chondro/dermato-lyases.
Results: Direct analysis of aqueous CS solutions from various
tissues ensured the complete separation and identification of CS
and HA. Selective enzymic digestion of various CS preparations
with chondroitinases and analysis under the same CE condi-
tions, ensures the complete separation between the sulphated
CS-disaccharides and HA within 15 min. Analysis as low as
50 μg of CS preparations can be used to identify even 0.3%
HA contamination. For analysis of serum samples CS chains
were completely recovered by precipitation. Following enzymic
treatments and CE analysis, the composition of disaccharides in
serum was found to be rich in 4-sulphated and non-sulphated
CS-derived disaccharides.
Conclusions: The developed methodological approach is sensi-
tive and accurate and can be easily used for the identification of
HA contamination in commercially available preparations of CS,
the charge homogeneity of CS as well as for the determination of
the CS concentration and sulphation profile in blood serum. The
approach will be useful for pharmacokinetic studies and disease
monitoring.
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Purpose: Pentosidine (PEN), a major member of advanced
glycation end-products, belongs to promising molecules that el-
evated concentrations in body fluids and tissues could indicate
deleterious changes caused by specific post-translational modi-
fication in metabolism of long-lived proteins, lipids, and carbohy-
drates. Quantification of PEN in body fluids or tissues by means
of sensitive HPLC methods helps to monitor the pathological
modifications of proteins in a number of diseases.
In this study, we determined PEN in patients with diabetes mel-
litus (DM) and rheumatic diseases. For that, highly sensitive
and reproducible HPLC method combined with sensitive fluores-
cent detection was developed. Then we determined PEN levels
in biological samples from laboratory mice (C57/6 black) with
spontaneously induced arthritis. To analyze reduced formation of
PEN in vivo, we tested antioxidative and antirheumatic effects of
vitamin C and Boswellin supplementation of these mice.
Methods: For PEN determination we established sensitive
method based on reversed phase gradient HPLC combined
with fluorescence detection (λexc./λem. = 335/385 nm). The con-
ditions are as follows: compact glass column CGC Separon SGX
C18, 150x3 mm; mobile phase consisted of 0.02 M heptaflu-
orobutyric acid, 0.01M ammonium sulphate and linear gradient
is given by variable concentration of acetonitrile (12.5 - 25%),
column temperature: 40°C; flow rate: 0.5 ml/min; time of HPLC
run: 30 minutes. The method was applied to hydrolyzed and pu-
rified body fluid samples from patients with osteoarthritis (OA),
rheumatoid arthritis (RA), diabetics of type 1 (DM1) and type 2
(DM2), healthy controls as well as to samples from serum and
experimental mice tissue extracts.
Results: In blood samples of patients with RA and DM2, the ac-
cumulation of PEN was doubled compared with healthy controls.
In case of OA patients, mild elevation of PEN was also observed.
We found significant correlation of PEN concentrations between
studied body fluids. The association of PEN concentrations with
the age of studied subjects was observed.
